363 results on '"Uchiyama, Hitoji"'
Search Results
2. Frontline use of rituximab may prevent ADAMTS13 inhibitor boosting during caplacizumab treatment in patients with iTTP: post hoc analysis of a phase 2/3 study in Japan
3. Negative impact of immunoparesis in response to anti-SARS-CoV-2 mRNA vaccination of patients with multiple myeloma
4. Real-world practice-based prognostic model for higher-risk myelodysplastic syndromes treated with azacitidine monotherapy: The Kyoto prognostic scoring system
5. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin
6. The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study
7. NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia
8. Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study
9. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia
10. Impact of event-free survival status after stem cell transplantation on subsequent survival of patients with lymphoma
11. Clinical impacts of severe thrombocytopenia in the first cycle of azacitidine monotherapy and cytogenetics in patients with myelodysplastic syndrome: The Kyoto Conditional Survival Scoring System
12. Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial
13. MO49-5 Efficacy and safety of R-THP-COP therapy for elderly patients with untreated diffuse large B-cell lymphoma
14. Outcome of stem cell transplantation for Waldenström’s macroglobulinemia: analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group
15. Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma
16. Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults: 25 years of experience in Japan
17. Recurrent intragenic exon rearrangements of SOBP and AUTS2 in non-Hodgkin B-cell lymphoma
18. Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia
19. Iguratimod triggers the relapse of methotrexate-associated lymphoproliferative disorder
20. Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study
21. Immunosuppressive therapy with rabbit antithymocyte globulin therapy for acquired aplastic anemia: a multi-institutional retrospective study in Japanese adult patients
22. Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma
23. Comparison of Autologous and Unrelated Transplants for Cytogenetically Normal Acute Myelogenous Leukemia
24. Gastric lymphoma complicated by phlegmonous gastritis and Guillain–Barré syndrome: A case report
25. Diffuse large B cell lymphoma with chromosomal translocation t(14;19)(q32;q13) occurring in IgG4-related disease
26. Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum
27. Impact of Treatment with Anti-CD20 Monoclonal Antibody on the Production of Neutralizing Antibody Against Anti–SARS-CoV-2 Vaccination in Mature B-Cell Neoplasms
28. Cardiac involvement of malignant lymphoma presenting intra-ventricular-wall nodules
29. Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia
30. Impact of Treatment with Anti-CD20 Monoclonal Antibody on the Production of Neutralizing Antibody Against Anti–SARS-CoV-2 Vaccination in Mature B-Cell Neoplasms
31. Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum
32. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin
33. The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study
34. Mutational Analysis of DNMT3A Improves the Prognostic Stratification Using NPM1/FLT3-ITD Genotypes in Patients with Acute Myeloid Leukemia
35. Optical frequency domain imaging-guided rotational atherectomy followed by drug-coated balloon dilation to the non-calcified lesion in a patient with severe thrombocytopenia
36. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin
37. Simultaneous detection ofJAK2,CALR, andMPLmutations and quantitation ofJAK2 V617Fallele burden in myeloproliferative neoplasms using the quenching probe‐Tm method in i‐densy IS ‐5320
38. Prognostic impact of a past or synchronous second cancer in diffuse large B cell lymphoma
39. Tandem autologous stem cell transplantation in elderly patients with myeloma: A multicenter retrospective analysis.
40. The longitudinal analysis of large granular lymphocytosis in patients with Philadelphia chromosome-positive leukemia treated with dasatinib
41. Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma
42. Successful treatment of paraneoplastic pemphigus and bronchiolitis obliterans associated with follicular lymphoma with obinutuzumab and bendamustine
43. sj-docx-13-tah-10.1177_20406207221142487 – Supplemental material for Monocyte or white blood cell counts and β2 microglobulin predict the durable efficacy of daratumumab with lenalidomide
44. Serum Albumin Levels Strongly Predict Survival Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab-Combined Chemotherapy
45. The Efficacy and Safety of Caplacizumab in Japanese Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): An Open-Label, Phase 2/3 Study
46. 65 - Impact of Event-Free Survival Status after Stem Cell Transplantation on Subsequent Survival in Lymphoma Patients
47. Long-Term Maintenance of Hematological and Cytogenetic Remission in 5q- Syndrome After Short-Term Administration of Lenalidomide
48. A treatment refractory CD30-positive diffuse large B cell lymphoma in the ileal neobladder
49. Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma
50. Morphological analysis of biofilm of peritoneal dialysis catheter in refractory peritonitis patient
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.